Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : FPA Medical Management - FPAMQ -- Ignore unavailable to you. Want to Upgrade?

To: Kurthend who wrote (859)	7/7/1998 10:06:00 PM
From: Richard D	Read Replies (1) \| Respond to of 1110

Kurt, If you're on any heart medication, I'd stay away from the stock. Having said that, it appears we are basing here with strong support above 1. Raymond James gave a mixed report, but said they expect a "slew" of press releases in the coming weeks. Maybe they'll push it up. It's down for a reason and is a high-risk/high reward stock obviously. Richard

To: Kurthend who wrote (859)	7/8/1998 12:37:00 AM
From: Douglas V. Fant	Respond to of 1110

Kurt, No great rush here to enter, but note that that the technical underpinnings of FPAM continue to improve. Today the Moving Average Convergence/Divergence Line now flipped to a bullish reading. Still a "news driven" stock, and still technically looking downward overall, but... still, looking a little bit better after today's action.... Just a rough calculation, but if you assume a going enterprise value for FPAM of $400mm post "reequitization" (Whew! sound like Dizzy Dean), and 42mm shares outstanding, even with a 75% dilution of the current share base (worst case scenario) to 168mm shares outstanding, we should still have a book value of around $2.50/share.... So no rush, but don't sit on the sideline too long... Sincerely, Doug F. PS Daytraders could have made money on the "down, then up" daily pattern of FPAM again today....